GlassScriptPhysician profile
Boris Mosheyev
NPI 1740726181
$2,618.45
in general payments reported to CMS, 2019-2025
22 companies · $776 in 2025
The $776 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $533 · 2022: $246 · 2023: $430 · 2024: $634 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,839.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $537.97 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $419.03 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $322.01 | 2021-2025 | Relistor, Xifaxan, Trulance |
| Scilex Pharmaceuticals INC. | $255.66 | 2021-2024 | |
| Intra-Sana Laboratories | $162.96 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Otsuka America Pharmaceutical, INC. | $150.00 | 2025 | Rexulti |
| Viiv Healthcare Company | $125.95 | 2024-2025 | Dovato |
| Amgen INC. | $104.33 | 2023-2025 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $100.99 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $84.17 | 2023-2025 | |
| Pfizer INC. | $76.90 | 2021 | |
| Novo Nordisk INC | $48.18 | 2021-2025 | Ozempic |
| Amarin Pharma, INC. | $44.81 | 2021-2022 | |
| Gilead Sciences, INC. | $34.78 | 2021-2023 | |
| Corcept Therapeutics | $23.70 | 2024 | Korlym |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $23.69 | 2024 | |
| Glaxosmithkline, LLC. | $21.04 | 2023 | Shingrix, Trelegy Ellipta |
| Nestle Healthcare Nutrition INC. | $19.83 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.89 | 2022 | |
| Merck Sharp & Dohme LLC | $15.71 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.93 | 2023 | Fasenra |
| Horizon Therapeutics Plc | $13.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Mosheyev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.